Search Contact
This page is available in multiple languages
Select Language

Fine Foods & Pharmaceuticals N.T.M. S.p.A. moves from AIM Italia to Borsa Italiana’s STAR segment

Back

  • Third move to Borsa Italiana’s STAR segment in 2021
  • Fine Foods & Pharmaceuticals N.T.M. S.p.A. brings the total number of companies listed on Borsa Italiana’s STAR segment to 80

Milan – 12 July 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Fine Foods & Pharmaceuticals N.T.M. S.p.A. on its move from AIM Italia to Borsa Italiana’s STAR segment.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. is an Italian independent CDMO (Contract Development and Manufacturing Organisation) that develops and manufactures contract products for the pharmaceutical and nutraceutical industry.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. listed on Borsa Italiana’s AIM Italia in October 2018. The company is the twelfth firm to move from AIM Italia to Borsa Italiana’s STAR segment, bringing the total number of companies listed on Borsa Italiana’s STAR segment to 80.

Marco Francesco Eigenmann, Chairman and CEO of Fine Foods & Pharmaceuticals N.T.M. S.p.A., said: ”The transition to the STAR segment was one of Fine Foods’ objectives when it first listed on AIM Italia. Today, we can say that we kept our promise to the market. This transition will allow us to create new growth opportunities, organic and by  acquisitions, and to access an ever-wider range of Italian and international investors. This achievement, strengthened by our business model based on solid governance, unrivalled R&D, a passion for innovation and a holistic ESG approach, is the beginning of a new journey that will generate further value for all our stakeholders. I want to thank Borsa Italiana, who assisted and supported us in this historic milestone for the company, our consultants, our employees and all those who helped us to make this operation possible.”

Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical and nutraceutical industry; the Fine Foods Group is also active in the cosmetics, biocides and medical devices industries with its recent acquisition of Pharmatek-PMC. Founded in 1984, from a pharmaceutical and nutraceutical synergy, Fine Foods has been pursuing quality and innovation on behalf of its customers as its primary objective. With €172 million in revenue in 2020 and an 11% CAGR over the last decade, it is a growing and future-oriented company. The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the Group to fully develop its intrinsic potential.

Download press release - Fine Foods S.p.A.

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway, and Portugal. As of March 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway, and Portugal host nearly 1,800 listed issuers with around €6.3 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices. 
For the latest news, follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.